(Date:12/16/2009)... 16 /PRNewswire/ -- Capitalizing ... sciences industry and an active venture capital market, ... State Teachers Retirement Fund, Indiana University, Purdue University, ... Foundation, and Credit Suisse today announced the establishment ... capital fund of funds. ,, Organized through BioCrossroads, ...
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), today announced ... David Pendarvis to its board of directors. ... F. Buechler, Ph.D., was president, chief scientific officer ... 1994, Dr. Buechler was Biosite,s director of chemistry. ... senior research scientist for the diagnostics research and ...
(Date:12/16/2009)... Eppendorf has initiated an,import ban for Nanosphere, ... of European patent EP 1 179 180 ... quantification of a target compound". The import,ban ... respective products into any country of,the European ... any,violating products. , ...
(Date:12/15/2009)... 15 Epeius Biotechnologies Corporation, an emerging ... gained international validation of the cutting-edge science behind ... scientists around the world rediscovered the Cyclin ... of cancer pathogenesis and disease progression, and thus ... at the NIH National Cancer Institute investigating the ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3... 1,200 new, jobs within 36 months of initiating operations in its second ... ... St. Jude,Medical, Inc. (NYSE: STJ ) today announced plans to expand ... Industrial Park, which will allow the company to increase its,Puerto Rico operations by ...
... Coulter,Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing,announced today that Charles Slacik, ... will present at the 2007 UBS Global,Life Sciences ... p.m.,(EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
Other Biology Technology:St. Jude Medical to Expand Puerto Rico Operations 2Beckman Coulter to Present at the UBS Global Life Sciences Conference 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7(Date:12/16/2009)... iQor, a global provider of business process ... InfoWorld 100 Awards Top 100 IT project of ... the first submission for iQor. ,, "We are honored ... said Vikas Kapoor, president and CEO of iQor. "TeQ21 ... us to work faster, smarter and with the added ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... safety and finger-based biometric identification solutions, announced ... a Special Shareholder Meeting held today approved ... Division to Interact911 Mobile Systems Inc. Of ... favor and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 1AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 7US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7A crystal ball for brain cancer 3F 54598 1A crystal ball for brain cancer 3F 54598 2A crystal ball for brain cancer 3F 54598 3dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Equine IL-4, CF...
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
...
Biology Products:Biology NavigationMedical Navigation